AIM ImmunoTech (NYSE:AIM) Shares Down 1.5%

AIM ImmunoTech Inc. (NYSE:AIM)’s stock price was down 1.5% during mid-day trading on Friday . The stock traded as low as $0.36 and last traded at $0.38. Approximately 131,930 shares changed hands during trading, a decline of 44% from the average daily volume of 234,735 shares. The stock had previously closed at $0.38.

AIM ImmunoTech Stock Down 1.5 %

The company has a market capitalization of $19.47 million, a P/E ratio of -0.59 and a beta of -0.35. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 0.23. The stock has a 50 day moving average price of $0.39 and a 200 day moving average price of $0.42.

AIM ImmunoTech (NYSE:AIM) last posted its earnings results on Thursday, May 16th. The company reported ($0.12) earnings per share for the quarter. The business had revenue of $0.04 million for the quarter. AIM ImmunoTech had a negative return on equity of 191.38% and a negative net margin of 16,123.32%.

Insider Buying and Selling at AIM ImmunoTech

In other news, CEO Thomas K. Equels bought 61,729 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was acquired at an average price of $0.41 per share, with a total value of $25,308.89. Following the transaction, the chief executive officer now owns 778,184 shares of the company’s stock, valued at approximately $319,055.44. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).